9 February 2023 - EMA opinion on AVT04 could come as soon as the second half of 2023. ...
6 February 2023 - Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration and diabetic macular oedema is based ...
27 January 2023 - Eisai and Biogen announced today that the EMA has accepted a marketing authorisation application for lecanemab, an ...
23 January 2023 - Arpraziquantel is the first investigational drug in regulatory phase amongst the different projects supported by the Global ...
11 January 2023 - Eisai and Biogen announced today that Eisai has submitted a marketing authorisation application for lecanemab, an investigational ...
6 January 2023 - Biologic license application designated priority review by FDA and seeks approval for rozanolixizumab for the treatment ...
4 January 2022 - Submission based on DESTINY-Lung02 and DESTINY-Lung01 Phase 2 trial results which showed Daiichi Sankyo and AstraZeneca’s Enhertu ...
3 January 2023 - Janssen today announced the submission of a marketing authorisation application to the EMA seeking approval of ...
3 January 2023 - Application based on statistically significant and clinically meaningful overall survival and progression-free survival results from the Phase ...
4 January 2023 - BioMarin submits supplemental new drug application to US FDA to expand label to treat children with achondroplasia ...
22 December 2022 - Submission follows the US FDA acceptance of the ONS-5010 BLA for wet AMD, with a PDUFA ...
21 December 2022 - Sobi and ADC Therapeutics today announced that the European Commission has granted conditional marketing authorisation for the ...
21 December 2022 - Filings based on two Phase 3 trials demonstrating significant clinical remission versus placebo and safety profile ...
19 December 2022 - Gold standard Phase 3 ASSERT study supports supplementary filings in the US and EU. ...
16 December 2022 - Apellis Pharmaceuticals today announced that the company has submitted a marketing authorisation application to the European Medicines ...